Olema Pharmaceuticals, Inc.

NasdaqGS:OLMA 주식 보고서

시가총액: US$661.5m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Olema Pharmaceuticals 관리

관리 기준 확인 4/4

Olema Pharmaceuticals' CEO는 Sean Bohen, Sep2020 에 임명되었습니다 의 임기는 4.08 년입니다. 총 연간 보상은 $ 3.15M, 20.5% 로 구성됩니다. 20.5% 급여 및 79.5% 보너스(회사 주식 및 옵션 포함). 는 $ 1.73M 가치에 해당하는 회사 주식의 0.25% 직접 소유합니다. 1.73M. 경영진과 이사회의 평균 재임 기간은 각각 4.1 년과 4.2 년입니다.

주요 정보

Sean Bohen

최고 경영자

US$3.2m

총 보상

CEO 급여 비율20.5%
CEO 임기4.1yrs
CEO 소유권0.3%
경영진 평균 재임 기간4.1yrs
이사회 평균 재임 기간4.2yrs

최근 관리 업데이트

Recent updates

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Aug 29
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Olema Pharmaceuticals: Still Merits A Small Holding

Jun 17

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

May 11
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Mar 28

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Mar 04
Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Jun 11
We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Mar 01
Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Olema Oncology grants stock options for 58.3K shares

Oct 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 13
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18

Aug 09

Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype

Jul 21

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

May 29
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 08
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Our Take On Olema Pharmaceuticals

Jan 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 19
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Jun 04
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 19
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

CEO 보상 분석

Sean Bohen 의 보수는 Olema Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$110m

Mar 31 2024n/an/a

-US$99m

Dec 31 2023US$3mUS$647k

-US$97m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$97m

Mar 31 2023n/an/a

-US$110m

Dec 31 2022US$6mUS$616k

-US$105m

Sep 30 2022n/an/a

-US$100m

Jun 30 2022n/an/a

-US$95m

Mar 31 2022n/an/a

-US$79m

Dec 31 2021US$3mUS$595k

-US$71m

Sep 30 2021n/an/a

-US$60m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$11mUS$178k

-US$24m

보상 대 시장: Sean 의 총 보상 ($USD 3.15M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 3.43M ).

보상과 수익: Sean 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Sean Bohen (57 yo)

4.1yrs

테뉴어

US$3,152,370

보상

Dr. Sean P. Bohen, M.D., Ph.D. has been a Director at AltruBio, Inc. He is the Chief Executive Officer and Director of Olema Pharmaceuticals, Inc. since September 2020 and serves as its President. He serve...


리더십 팀

이름위치테뉴어보상소유권
Sean Bohen
President4.1yrsUS$3.15m0.25%
$ 1.7m
Shane William Kovacs
Chief Operating & Financial Officer4.3yrsUS$1.55m0.85%
$ 5.6m
Naseem Zojwalla
Chief Medical Officer2.8yrsUS$1.30m0.16%
$ 1.0m
Julie Dexter
Senior VP & Head of Peopleno data데이터 없음데이터 없음
David Myles
Chief Discovery & Non-Clinical Development Officer4.3yrsUS$200.00k1.3%
$ 8.6m
Demiana Faltaos
VP & Head of Clinical Pharmacologyno data데이터 없음데이터 없음
John Moriarty
Corporate Secretary4.1yrsUS$3.27m데이터 없음
Sasha Austin
VP of Finance & Controller1.8yrs데이터 없음데이터 없음

4.1yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: OLMA 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Sean Bohen
President4.1yrsUS$3.15m0.25%
$ 1.7m
Andrew Rappaport
Independent Director11.8yrsUS$176.65k0.67%
$ 4.5m
Cynthia Butitta
Independent Director4.2yrsUS$180.15k0.15%
$ 969.6k
Ian T. Clark
Independent Chairperson of the Board4.2yrsUS$198.65k0%
$ 0
Frank McCormick
Chairman of Scientific Advisory Board3.5yrsUS$11.81k데이터 없음
Pamela M. Klein
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Sandra Horning
Independent Director3.9yrsUS$158.15k0%
$ 0
Scott Garland
Independent Directorless than a yearUS$280.21k0%
$ 0
Graham L. Walmsley
Independent Director4.6yrsUS$171.15k0%
$ 0
Yi Larson
Independent Director3.5yrsUS$163.15k0%
$ 0
Gorjan Hrustanovic
Independent Director6.3yrsUS$165.15k0%
$ 0
Cyrus Harmon
Director18.2yrsUS$1.33m1.53%
$ 10.1m

4.2yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: OLMA 의 이사회경험(평균 재직 기간 3.8 년)으로 간주됩니다.